That's exactly the point. The selective classes (SNRI/SSRI) are marketed as a complete and safe replacement for MAOIs, on top of the chemical structure irony. Even the new atypicals with innovative chemical structure (and targets other than 5-HT1/SERT) are of significantly worse efficacy MAOIs

I'll edit my parent comment to make it clearer.

I don’t quite get the point you’re making then, as there’s a lot of generic citralopam on the market, despite escitralopam being patented.